scholarly journals Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality

Cancers ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 976
Author(s):  
Amanda Dibden ◽  
Judith Offman ◽  
Stephen W. Duffy ◽  
Rhian Gabe
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Mammography Screening ◽  
Meta Analysis ◽  
Breast Cancer Mortality ◽  
Substantial Reduction ◽  
Healthcare Setting ◽  
Actual Attendance

In 2012, the Euroscreen project published a review of incidence-based mortality evaluations of breast cancer screening programmes. In this paper, we update this review to October 2019 and expand its scope from Europe to worldwide. We carried out a systematic review of incidence-based mortality studies of breast cancer screening programmes, and a meta-analysis of the estimated effects of both invitation to screening and attendance at screening, with adjustment for self-selection bias, on incidence-based mortality from breast cancer. We found 27 valid studies. The results of the meta-analysis showed a significant 22% reduction in breast cancer mortality with invitation to screening, with a relative risk of 0.78 (95% CI 0.75–0.82), and a significant 33% reduction with actual attendance at screening (RR 0.67, 95% CI 0.61–0.75). Breast cancer screening in the routine healthcare setting continues to confer a substantial reduction in mortality from breast cancer.

Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening

2009 ◽  
Vol 27 (35) ◽  
pp. 5919-5923 ◽  
Author(s):  
Philippe Autier ◽  
Clarisse Héry ◽  
Jari Haukka ◽  
Mathieu Boniol ◽  
Graham Byrnes
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Advanced Breast Cancer ◽  
Breast Cancer Screening ◽  
Advanced Cancer ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Advanced Breast ◽  
Published Data ◽  
National Breast

Purpose We assessed changes in advanced cancer incidence and cancer mortality in eight randomized trials of breast cancer screening. Patients and Methods Depending on published data, advanced cancer was defined as cancer ≥ 20 mm in size (four trials), stage II+ (four trials), and ≥ one positive lymph node (one trial). For each trial, we obtained the estimated relative risk (RR) and 95% CI between the intervention and control groups, for both breast cancer mortality and diagnosis of advanced breast cancer. Using a meta-regression approach, log(RR-mortality) was regressed on log(RR-advanced cancer), weighting each trial by the reciprocal of the square of the standard error of log(RR) for mortality. Results RR for advanced breast cancer ranged from 0.69 (95% CI, 0.61 to 0.78) in the Swedish Two-County Trial to 0.97 (95% CI, 0.97 to 1.25) in the Canadian National Breast Screening Study-1 (NBSS-1) trial. Log(RR)s for advanced cancer were highly predictive of log(RR)s for mortality (R2 = 0.95; P < .0001), and the linear regression curve had a slope of 1.00 (95% CI, 0.76 to 1.25) after fixing the intercept to zero. The slope changed only slightly after excluding the Two-County Trial and the Canadian NBSS-1 and NBSS-2 trials. Conclusion In trials on breast cancer screening, for each unit decrease in incidence of advanced breast cancer, there was an equal decrease in breast cancer mortality. Monitoring of incidence of advanced breast cancer may provide information on the current impact of screening on breast cancer mortality in the general population.

Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10500-10500
Author(s):  
Kathryn P. Lowry ◽  
H. Amarens Geuzinge ◽  
Natasha K. Stout ◽  
Oguzhan Alagoz ◽  
John M. Hampton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Breast Cancer Incidence ◽  
Simulation Models ◽  
Pathogenic Variants ◽  
Life Years ◽  
Incidence And Mortality

10500 Background: Inherited pathogenic variants in ATM, CHEK2, and PALB2 confer moderate to high risks of breast cancer. The optimal approach to screening in these women has not been established. Methods: We used two simulation models from the Cancer Intervention and Surveillance Modeling Network (CISNET) and data from the Cancer Risk Estimates Related to Susceptibility consortium (CARRIERS) to project lifetime breast cancer incidence and mortality in ATM, CHEK2, and PALB2 carriers. We simulated screening with annual mammography from ages 40-74 alone and with annual magnetic resonance imaging (MRI) starting at ages 40, 35, 30, and 25. Joint and separate mammography and MRI screening performance was based on published literature. Lifetime outcomes per 1,000 women were reported as means and ranges across both models. Results: Estimated risk of breast cancer by age 80 was 22% (21-23%) for ATM, 28% (26-30%) for CHEK2, and 40% (38-42%) for PALB2. Screening with MRI and mammography reduced breast cancer mortality by 52-60% across variants (Table). Compared to no screening, starting MRI at age 30 increased life years (LY)/1000 women by 501 (478-523) in ATM, 620 (587-652) in CHEK2, and 1,025 (998-1,051) in PALB2. Starting MRI at age 25 versus 30 gained 9-12 LY/1000 women with 517-518 additional false positive screens and 197-198 benign biopsies. Conclusions: For women with ATM, CHEK2, and PALB2 pathogenic variants, breast cancer screening with MRI and mammography halves breast cancer mortality. These mortality benefits are similar to those for MRI screening for BRCA1/2 mutation carriers and should inform practice guidelines.[Table: see text]

scholarly journals Breast cancer screening case–control study design: impact on breast cancer mortality

2011 ◽  
Vol 22 (4) ◽  
pp. 863-869 ◽  
Author(s):  
E. Paap ◽  
A.L.M. Verbeek ◽  
D. Puliti ◽  
E. Paci ◽  
M.J.M. Broeders
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Study Design ◽  
Cancer Mortality ◽  
Case Control Study ◽  
Breast Cancer Mortality ◽  
Case Control ◽  
Control Study

Effectiveness of Mammography Screening in Reducing Breast Cancer Mortality in Women Aged 39–49 Years: A Meta-Analysis

2011 ◽  
Vol 20 (6) ◽  
pp. 845-852 ◽  
Author(s):  
Maria C. Magnus ◽  
Ma Ping ◽  
Miao Miao Shen ◽  
John Bourgeois ◽  
Jeanette H. Magnus
Keyword(s):  
Breast Cancer ◽  
Cancer Mortality ◽  
Mammography Screening ◽  
Meta Analysis ◽  
Breast Cancer Mortality

scholarly journals Breast cancer screening with mammography in women aged 40–49 years: Impact of length of screening interval on effectiveness of the program

2020 ◽  
pp. 096914132091828
Author(s):  
Zheng Mao ◽  
Lennarth Nyström ◽  
Håkan Jonsson
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Screening Program ◽  
Breast Cancer Mortality ◽  
Interval Cancers ◽  
Screening Interval ◽  
Using Data ◽  
The Impact

Objectives To estimate the impact on the effectiveness of Swedish breast cancer screening program in women aged 40–49 years of shortening the screening interval from 21 months to 18 or 12 months. Methods The reduction in breast cancer mortality among participants in screening with mammography was previously estimated in the Swedish SCReening of Young women (SCRY) study to be 29%. The expected increased effectiveness with a hypothetical shorter screening interval than the average of 21 months in SCRY was calculated using data about the women who died from breast cancer even though they participated in the SCRY program. Results During the study period, 547 women who participated in the index screening round died from breast cancer. Shortening the screening interval to 18 months led to an improved effectiveness of 0.7–3.9% considering interval cancers only and of 1.3–7.6% considering screening-detected cancers only, and for both interval and screening-detected cancers the improvement was 1.9–11.5% when the assumed mortality reduction for the deceased cases varied from 5% to 30%. Shortening the screening interval to 12 months increased the effectiveness by 1.6–9.8% for interval cancers and by 2.9–17.4% for both interval and screening-detected cancers. Conclusion Shortening the screening interval for women aged 40–49 years to 18 or 12 months might further reduce the breast cancer mortality rate.

scholarly journals The Gothenburg Breast Cancer Screening Trial: Preliminary Results on Breast Cancer Mortality for Women Aged 39-49

1997 ◽  
Vol 1997 (22) ◽  
pp. 53-55 ◽  
Author(s):  
Nils Bjurstam ◽  
Lena Björneld ◽  
Stephen W. Duffy ◽  
Teresa C. Smith ◽  
Erling Cahlin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Preliminary Results ◽  
Cancer Screening Trial ◽  
Screening Trial

scholarly journals Balancing the benefits and detriments among women targeted by the Norwegian Breast Cancer Screening Program

2016 ◽  
Vol 23 (4) ◽  
pp. 203-209 ◽  
Author(s):  
Solveig Hofvind ◽  
Marta Román ◽  
Sofie Sebuødegård ◽  
Ragnhild S Falk
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Screening Program ◽  
Breast Cancer Mortality ◽  
Cancer Death ◽  
Breast Cancer Death ◽  
Breast Cancer Screening Program ◽  
Cancer Screening Program

Objective To compute a ratio between the estimated numbers of lives saved from breast cancer death and the number of women diagnosed with a breast cancer that never would have been diagnosed during the woman’s lifetime had she not attended screening (epidemiologic over-diagnosis) in the Norwegian Breast Cancer Screening Program. Methods The Norwegian Breast Cancer Screening Program invites women aged 50–69 to biennial mammographic screening. Results from published studies using individual level data from the programme for estimating breast cancer mortality and epidemiologic over-diagnosis comprised the basis for the ratio. The mortality reduction varied from 36.8% to 43% among screened women, while estimates on epidemiologic over-diagnosis ranged from 7% to 19.6%. We computed the average estimates for both values. The benefit–detriment ratio, number of lives saved, and number of women over-diagnosed were computed for different scenarios of reduction in breast cancer mortality and epidemiologic over-diagnosis. Results For every 10,000 biennially screened women, followed until age 79, we estimated that 53–61 (average 57) women were saved from breast cancer death, and 45–126 (average 82) were over-diagnosed. The benefit–detriment ratio using average estimates was 1:1.4, indicating that the programme saved about one life per 1–2 women with epidemiologic over-diagnosis. Conclusion The benefit–detriment ratio estimates of the Norwegian Breast Cancer Screening Program, expressed as lives saved from breast cancer death and epidemiologic over-diagnosis, should be interpreted with care due to substantial uncertainties in the estimates, and the differences in the scale of values of the events compared.

scholarly journals Repeated mammographic screening reduces breast cancer mortality along the continuum of age

2002 ◽  
Vol 9 (4) ◽  
pp. 163-167 ◽  
Author(s):  
M.J.M. Broeders ◽  
A.L.M. Verbeek ◽  
H. Straatman ◽  
P.G.M. Peer ◽  
P.C.M. Pasker-de Jong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Screening Programme ◽  
Breast Cancer Mortality ◽  
Mammographic Screening ◽  
Protective Effects ◽  
Age Group ◽  
The Continuum

OBJECTIVE: The optimal age boundaries for breast cancer screening are still under debate. A case-referent design was used to describe the effect of mammographic screening on breast cancer mortality along the continuum of age, based on a 20 year follow up period. SETTING: The population based breast cancer screening programme in Nijmegen, The Netherlands, which has biennially invited women over 35 years since 1975. METHODS: Cases, defined as women who died from primary breast cancer between 1987 and 1997, were selected from the group of women who received at least one invitation to the screening programme. For 157 cases, 785 women from the same group were selected as referents. Information on the index screening (the screening examination preceding diagnosis of the case) was collected for both cases and referents. The risk of dying from breast cancer was calculated per 10 year moving age group for women who had attended the index screening versus those who had not. RESULTS: The youngest 10 year age group showing an effect in our study were women aged 45–54 at their index screening. Breast cancer mortality for women in this group who attended the index screening was 32% lower, although not significant, than for women who did not (odds ratio (OR) 0.68, 95% confidence interval (95% CI) 0.33 to 1.41). This reduction in risk was not explained solely by an effect in women over 50 because the OR in women aged 45–49 was 0.56 (95% CI 0.20 to 1.61). Reductions in mortality became smaller with increasing age. Nevertheless, for women over 60 at index screening, participation in screening over a maximum 4 year period before diagnosis of the case yielded protective effects at least up to an age around 80. CONCLUSIONS: Although our results are based on a relatively small number of cases, they suggest that even in a programme with a 2 year screening interval there may be a benefit of starting screening around age 45. Also older women who participate at least once every 4 years still have much to gain from screening.

Sign in / Sign up

Export Citation Format

Share Document